Unicycive Q1 net loss $21.2M ($0.61/sh); OLC pivotal topline due Q2 2024

Unicycive Therapeutics, Inc.

2024-Q1 EPS reported -$0.61

Net loss $21.2M ($0.61/sh) vs $14.8M ($0.97) in Q1 2023; R&D expenses rose to $6.8M from $3.0M.
Cash $48.9M at March 31, 2024; funded operations expected into 2026.
Topline data from OLC pivotal trial in CKD on dialysis expected in Q2 2024.
UNI-494 Phase 1 MAD portion ongoing; FDA orphan drug designation for prevention of DGF in kidney transplant.
Completed $50M private placement with healthcare institutional investors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unicycive Therapeutics, Inc. reported the three months ended March 31, 2024 results: net income Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s, EPS $0.61 per share of common stock.

Period: the three months ended March 31, 2024
Net income: Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s
EPS: $0.61 per share of common stock
Result: reported results

Exact text from the filing

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”) , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced its financial results for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-042338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.